Survival in mantle cell lymphoma after frontline treatment with R-bendamustine, R-CHOP and the Nordic MCL2 regimen – a real world study on patients diagnosed in Sweden 2007-2017

• Alexandra Albertsson-Lindblad,
• Thorgerdur Palsdottir,
• Karin E. Smedby,
• Caroline E. Weibull,
• Ingrid Glimelius,
• Mats Jerkeman

Affiliations

Alexandra Albertsson-Lindblad

Division of Oncology, Skane University Hospital, Lund University, Lund

Thorgerdur Palsdottir

Department of Medicine Solna, Clinical Epidemiology Division, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm

Karin E. Smedby

Department of Medicine Solna, Clinical Epidemiology Division, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden; Department of Medicine Solna, Division of Hematology, Karolinska University Hospital Stockholm

Caroline E. Weibull

Department of Medicine Solna, Clinical Epidemiology Division, Karolinska Institutet and Karolinska University Hospital, Stockholm

Ingrid Glimelius

Department of Medicine Solna, Clinical Epidemiology Division, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden; Department of Immunology, Genetics and Pathology, Clinical and Experimental Oncology, Uppsala University and Uppsala Akademiska Hospital

Mats Jerkeman

Division of Oncology, Skane University Hospital, Lund University, Lund